The Cage system can be utilized at one or two contiguous levels from L2-S1 from a posterior approach for lumbar interbody fusion. The device is comprised of two footprints with three varying degrees of lordosis and graft windows for maximum endplate-to-endplate contact. The product is currently in limited, controlled release and is targeted for full commercial launch by the fourth quarter.
Read the company news release about Medyssey Spine’s Cage System.
Read other coverage about FDA clearances:
– Integra LifeSciences Receives FDA 510(k) Clearance for 3 Spine Devices
– 22 Spine Devices Receive FDA 510(k) Clearance in March
– 56 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in March
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
